Advertisement

An integrated proteomic and glycoproteomic study for differences on glycosylation occupancy in rheumatoid arthritis

  • Xu Li
  • Lang Ding
  • Xue Li
  • He Zhu
  • Ebtesam A. Gashash
  • Zhanguo Li
  • Peng George WangEmail author
  • Cheng MaEmail author
Research Paper

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease in which certain immune cells are dysfunctional and attack their own healthy tissues. There has been great difficulty in finding an accurate and efficient method for the diagnosis of early-stage RA. The present shortage of diagnostic methods leads to the rough treatments of the patients in the late stages, such as joint removing. Nowadays, there is an increasing focus on glyco-biomarkers discovery for malicious disease via MS-based strategy. In this study, we present an integrated proteomics and glycoproteomics approach to uncover the pathological changes of some RA-related glyco-biomarkers and glyco-checkpoints involved in the RA onset. Among 39 distinctly expressive N-glycoproteins, 27 N-glycoproteins were discovered with over twofold expression significances. On the other hand, 13 proteins have been distinguished with significant differences in 53 distinctly expressed proteins identified in this study. Such an integrated approach will provide a comprehensive strategy for new potential glyco-biomarkers and checkpoints discovery in rheumatoid arthritis.

Keywords

Biomarker Label-free quantification Mass spectrometry Rheumatoid arthritis 

Notes

Acknowledgments

We sincerely thank Georgia Research Alliance (GRA) and Georgia State University for purchasing the analytical instrument used in this research.

Compliance with ethical standards

The study was approved by the Ethics Committee of Peking University People’s Hospital (Approval No. 2015 PHB 219-01). All participants of this study provided informed consent for participation in this study.

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

216_2018_1543_MOESM1_ESM.pdf (173 kb)
ESM 1 (PDF 173 kb)

References

  1. 1.
    Scott DL, Wolfe F, Huizinga WJH. Rheumatoid arthritis. Lancet. 2010;376:1094–108.CrossRefGoogle Scholar
  2. 2.
    Klareskog L, Padyukov L, Lorentzen J, Alfredsson L. Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006;2(8):425–33.CrossRefGoogle Scholar
  3. 3.
    Lindstrom TM, Robinson WH. Biomarkers for rheumatoid arthritis: making it personal. Scand J Clin Lab Investig Suppl. 2010;242:79–84.CrossRefGoogle Scholar
  4. 4.
    Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis. 2009;68(5):736–43.CrossRefGoogle Scholar
  5. 5.
    Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediat Inflamm. 2014;2014:545493.Google Scholar
  6. 6.
    Chard MD, Calvin J, Price CP, Cawston TE, Hazleman BL. Serum alpha 1 antichymotrypsin concentration as a marker of disease activity in rheumatoid arthritis. Ann Rheum Dis. 1988;47(8):665–71.CrossRefGoogle Scholar
  7. 7.
    Ha YJ, Kang EJ, Lee SW, Lee SK, Park YB, Song JS, et al. Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis. J Korean Med Sci. 2014;29(9):1199–204.CrossRefGoogle Scholar
  8. 8.
    Zhao J, Simeone DM, Heidt D, Anderson MA, Lubman DM. Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. J Proteome Res. 2006;5(7):1792–802.CrossRefGoogle Scholar
  9. 9.
    Varki ACR, Esko J, Freeze H, Hart G, Marth J. Essentials of glycobiology. New York: Cold spring harbor laboratory press; 1999.Google Scholar
  10. 10.
    Stevens J, Spang A. N-glycosylation is required for secretion and mitosis in C. elegans. PLoS One. 2013;8(5):e63687.CrossRefGoogle Scholar
  11. 11.
    Hart GW, Copeland RJ. Glycomics hits the big time. Cell. 2010;143(5):672–6.CrossRefGoogle Scholar
  12. 12.
    Huang Y, Wu H, Xue R, Liu T, Dong L, Yao J, et al. Identification of N-glycosylation in hepatocellular carcinoma patients’ serum with a comparative proteomic approach. PLoS One. 2013;8(10):e77161.CrossRefGoogle Scholar
  13. 13.
    Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology. 2007;17(12):1344–56.CrossRefGoogle Scholar
  14. 14.
    Vasseur JA, Goetz JA, Alley WR Jr, Novotny MV. Smoking and lung cancer-induced changes in N-glycosylation of blood serum proteins. Glycobiology. 2012;22(12):1684–708.CrossRefGoogle Scholar
  15. 15.
    Yoon SJ, Park SY, Pang PC, Gallagher J, Gottesman JE, Dell A, et al. N-glycosylation status of beta-haptoglobin in sera of patients with prostate cancer vs. benign prostate diseases. Int J Oncol. 2010;36(1):193–203.PubMedGoogle Scholar
  16. 16.
    Dennis JW, Granovsky M, Warren CE. Protein glycosylation in development and disease. BioEssays. 1999;21(5):412–21.CrossRefGoogle Scholar
  17. 17.
    Lowe JB. Glycan-dependent leukocyte adhesion and recruitment in inflammation. Curr Opin Cell Biol. 2003;15(5):531–8.CrossRefGoogle Scholar
  18. 18.
    Mechref Y, Hu Y, Garcia A, Hussein A. Identifying cancer biomarkers by mass spectrometry-based glycomics. Electrophoresis. 2012;33(12):1755–67.CrossRefGoogle Scholar
  19. 19.
    Kirwan A, Utratna M, O'Dwyer ME, Joshi L, Kilcoyne M. Glycosylation-based serum biomarkers for cancer diagnostics and prognostics. Biomed Res Int. 2015;2015:490531.CrossRefGoogle Scholar
  20. 20.
    Yang L, Zou QH, Zhang Y, Shi Y, Hu CR, Hui CX, et al. Proteomic analysis of plasma from rheumatoid arthritis patients with mild cognitive impairment. Clin Rheumatol. 2018;37(7):1773–82.CrossRefGoogle Scholar
  21. 21.
    Reiding KR, Vreeker G, Bondt A, Bladergroen MR, Hazes JM, van der Burgt YE, et al. Serum protein N-glycosylation changes with rheumatoid arthritis disease activity during and after pregnancy. Front Med (Lausanne). 2017;4:241.CrossRefGoogle Scholar
  22. 22.
    Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat Rev Immunol. 2008;8(11):874–87.CrossRefGoogle Scholar
  23. 23.
    Wisniewski JR, Zougman A, Mann M. Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome. J Proteome Res. 2009;8(12):5674–8.CrossRefGoogle Scholar
  24. 24.
    Ma C, Zhao X, Han H, Tong W, Zhang Q, Qin P, et al. N-linked glycoproteome profiling of human serum using tandem enrichment and multiple fraction concatenation. Electrophoresis. 2013;34(16):2440–50.CrossRefGoogle Scholar
  25. 25.
    Wang LH, Li DQ, Fu Y, Wang HP, Zhang JF, Yuan ZF, et al. pFind 2.0: a software package for peptide and protein identification via tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21(18):2985–91.CrossRefGoogle Scholar
  26. 26.
    Malovannaya A, Lanz RB, Jung SY, Bulynko Y, Le NT, Chan DW, et al. Analysis of the human endogenous coregulator complexome. Cell. 2011;145(5):787–99.CrossRefGoogle Scholar
  27. 27.
    Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64:5882–90.CrossRefGoogle Scholar
  28. 28.
    Kim EY, Lee MY, Kim SH, Ha K, Kim KP, Ahn YM. Diagnosis of major depressive disorder by combining multimodal information from heart rate dynamics and serum proteomics using machine-learning algorithm. Prog Neuro-Psychopharmacol Biol Psychiatry. 2017;76:65–71.CrossRefGoogle Scholar
  29. 29.
    Shiromizu T, Kume H, Ishida M, Adachi J, Kano M, Matsubara H, et al. Quantitation of putative colorectal cancer biomarker candidates in serum extracellular vesicles by targeted proteomics. Sci Rep. 2017;7(1):12782.CrossRefGoogle Scholar
  30. 30.
    Barker PE, Wagner PD, Stein SE, Bunk DM, Srivastava S, Omenn GS. Standards for plasma and serum proteomics in early cancer detection: a needs assessment report from the national institute of standards and technology--National Cancer Institute standards, methods, assays, reagents and technologies workshop, August 18-19, 2005. Clin Chem. 2006;52(9):1669–74.CrossRefGoogle Scholar
  31. 31.
    Crowgey EL, Wyffels JT, Osborn PM, Wood TT, Edsberg LE. A systems biology approach for studying heterotopic ossification: proteomic analysis of clinical serum and tissue samples. Genomics Proteomics Bioinformatics. 2018;16(3):212–20.CrossRefGoogle Scholar
  32. 32.
    Bunkenborg J, Pilch BJ, Podtelejnikov AV, Wisniewski JR. Screening for N-glycosylated proteins by liquid chromatography mass spectrometry. Proteomics. 2004;4(2):454–65.CrossRefGoogle Scholar
  33. 33.
    Kolarich D, Weber A, Turecek PL, Schwarz HP, Altmann F. Comprehensive glyco-proteomic analysis of human alpha1-antitrypsin and its charge isoforms. Proteomics. 2006;6(11):3369–80.CrossRefGoogle Scholar
  34. 34.
    Liang Y, Ma T, Thakur A, Yu H, Gao L, Shi P, et al. Differentially expressed glycosylated patterns of alpha-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer. Glycobiology. 2015;25(3):331–40.CrossRefGoogle Scholar
  35. 35.
    Topic A, Ljujic M, Radojkovic D. Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma. Hepat Mon. 2012;12(10 HCC):e7042.CrossRefGoogle Scholar
  36. 36.
    Chrostek L, Cylwik B, Gindzienska-Sieskiewicz E, Gruszewska E, Szmitkowski M, Sierakowski S. Sialic acid level reflects the disturbances of glycosylation and acute-phase reaction in rheumatic diseases. Rheumatol Int. 2014;34(3):393–9.CrossRefGoogle Scholar
  37. 37.
    McCarthy C, Saldova R, Wormald MR, Rudd PM, McElvaney NG, Reeves EP. The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions. J Proteome Res. 2014;13(7):3131–43.CrossRefGoogle Scholar
  38. 38.
    Sarrats A, Saldova R, Pla E, Fort E, Harvey DJ, Struwe WB, et al. Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin Appl. 2010;4(4):432–48.CrossRefGoogle Scholar
  39. 39.
    Zhao J, Fan YX, Yang Y, Liu DL, Wu K, Wen FB, et al. Identification of potential plasma biomarkers for esophageal squamous cell carcinoma by a proteomic method. Int J Clin Exp Pathol. 2015;8(2):1535–44.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Chen R, Jiang X, Sun D, Han G, Wang F, Ye M, et al. Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J Proteome Res. 2009;8(2):651–61.CrossRefGoogle Scholar
  41. 41.
    Liu T, Qian WJ, Gritsenko MA, Camp DG, Monroe ME, Moore RJ, et al. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res. 2005;4(6):2070–80.CrossRefGoogle Scholar
  42. 42.
    Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. The complement system and innate immunity. Immunobiology: the immune system in health and disease. 5th ed. New York: Garland Science; 2001.Google Scholar
  43. 43.
    Wouters D, Voskuyl AE, Molenaar ET, Dijkmans BA, Hack CE. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products. Arthritis Rheum. 2006;54(4):1143–50.CrossRefGoogle Scholar
  44. 44.
    Ritchie GE, Moffatt BE, Sim RB, Morgan BP, Dwek RA, Rudd PM. Glycosylation and the complement system. Chem Rev. 2002;102(2):305-20-19.CrossRefGoogle Scholar
  45. 45.
    Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, et al. Arthritis critically dependent on innate immune system players. Immunity. 2002;16(2):157–68.CrossRefGoogle Scholar
  46. 46.
    Ballanti E, Perricone C, di Muzio G, Kroegler B, Chimenti MS, Graceffa D, et al. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev. 2011;10(10):617–23.CrossRefGoogle Scholar
  47. 47.
    de Córdoba SR, Esparza-Gordillo J, de Jorge EG, Lopez-Trascasa M, Sánchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol. 2004;41(4):355–67.CrossRefGoogle Scholar
  48. 48.
    Stanley KK, Kocher HP, Luzio JP, Jackson P, Tschopp J. The sequence and topology of human complement component C9. EMBO J. 1985;4(2):375–82.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Xu Li
    • 1
  • Lang Ding
    • 1
  • Xue Li
    • 2
  • He Zhu
    • 1
  • Ebtesam A. Gashash
    • 1
  • Zhanguo Li
    • 2
  • Peng George Wang
    • 1
    Email author
  • Cheng Ma
    • 1
    Email author
  1. 1.Center for Diagnostics & Therapeutics and Department of ChemistryGeorgia State UniversityAtlantaUSA
  2. 2.Department of Rheumatology and ImmunologyPeking University People’s HospitalBeijingChina

Personalised recommendations